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abstract
PURPOSE Asparaginase-associated pancreatitis (AAP) is common in patients with acute lymphoblastic leukemia
(ALL), but risk differences across age groups both in relation to ﬁrst-time AAP and after asparaginase re-
exposure have not been explored.
PATIENTS AND METHODSWe prospectively registered AAP (n = 168) during treatment of 2,448 consecutive ALL
patients aged 1.0-45.9 years diagnosed from July 2008 to October 2018 and treated according to the Nordic
Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 protocol.
RESULTS Compared with patients aged 1.0-9.9 years, adjusted AAP hazard ratios (HRa) were associated with
higher age with almost identical HRa (1.6; 95% CI, 1.1 to 2.3; P = .02) for adolescents (10.0-17.9 years) and
adults (18.0-45.9 years). The day 280 cumulative incidences of AAPwere 7.0% for children (1.0-9.9 years: 95%
CI, 5.4 to 8.6), 10.1% for adolescents (10.0 to 17.9 years: 95% CI, 7.0 to 13.3), and 11.0% for adults (18.0-45.9
years: 95% CI, 7.1 to 14.9; P = .03). Adolescents had increased odds of both acute (odds ratio [OR], 5.2; 95%
CI, 2.1 to 13.2; P = .0005) and persisting complications (OR, 6.7; 95%CI, 2.4 to 18.4; P = .0002) compared with
children (1.0-9.9 years), whereas adults had increased odds of only persisting complications (OR, 4.1; 95% CI,
1.4 to 11.8; P = .01). Fifteen of 34 asparaginase-rechallenged patients developed a second AAP. Asparaginase
was truncated in 17/21 patients with AAP who subsequently developed leukemic relapse, but neither AAP nor
the asparaginase truncation was associated with increased risk of relapse.
CONCLUSION Older children and adults had similar AAP risk, whereas morbidity was most pronounced among
adolescents. Asparaginase re-exposure should be considered only for patients with an anticipated high risk of
leukemic relapse, because multiple studies strongly indicate that reduction of asparaginase treatment intensity
increases the risk of relapse.
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INTRODUCTION
Because adult patients now more frequently re-
ceive pediatric-inspired acute lymphoblastic leu-
kemia (ALL) treatment, their tolerance to such
therapy has become an important issue.1,2 De-
pending on the extent of asparaginase (ASP) ex-
posure, larger trials report asparaginase-associated
pancreatitis (AAP) in up to 11% of children with
ALL.3-16 Furthermore, premature withdrawal of ASP
reduces cure rates,3,4,17 and one of the commonest
causes of ASP truncation in children is AAP
because many experience a second AAP after ASP
rechallenge.3,5,18
ASP depletes the body of asparagine,19 interfering
with the highly active pancreatic protein synthesis.
Acute pancreatitis arises from premature activation of
trypsin within pancreatic acinar cells, acinar cell de-
struction, concomitant local inﬂammation, and ulti-
mately pancreatic autodigestion.20 However, the direct
mechanism behind AAP is unknown, and treatment
is mainly supportive.21 Although mortality is reported
in only a small percentage of patients,3,6,7,13,18,22 both
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acute and long-term morbidities after childhood AAP are
common.13,18,22-24
Some clinical3-9,15,18,25 and genetic5,9,26 risk factors for
acute pancreatitis have been proposed, including ado-
lescent age. However, comparative studies of pediatric
and adult patients with ALL, as well as studies exploring
the AAP-related morbidity and impact on leukemic re-
lapse risk, are missing. We investigated the cumulative
incidence, clinical characteristics, and relapse risk in
patients with ALL with AAP aged 1.0-45.9 years uniformly
treated according to the Nordic Society of Pediatric He-
matology and Oncology (NOPHO) ALL2008 protocol.
PATIENTS AND METHODS
Study Population
A total of 2,448 patients (including 168 patients with
AAP) aged 1.0-45.9 years with a diagnosis of either B-cell
precursor or T-cell Philadelphia chromosome-negative
ALL between July 2008 and October 2018 were in-
cluded. All patients were treated according to the NOPHO
ALL2008 protocol in Denmark, Estonia, Finland, Iceland,
Lithuania, Norway, and Sweden. An inclusion ﬂowchart is
presented in the Data Supplement.
All centers complied with mandatory registration of AAP
4 times a year throughout the study period.27,28 We iden-
tiﬁed patients with AAP in the NOPHO ALL registry on April
2, 2019, which provided data on patient, disease, and
antileukemic treatment. Detailed questionnaires in relation
to the diagnosis, complications, and outcome of AAP were
subsequently completed by local clinicians. The data were
merged with previously published data from 60% (80/134)
of the pediatric cohort.5
AAP-Related Deﬁnitions
The diagnosis of acute pancreatitis required fulﬁllment of
at least 2 of 3 diagnostic criteria: (1) abdominal pain;
(2) serum amylase (total or pancreas speciﬁc) or lipase
TABLE 1. AAP Characteristics
Characteristic All
Age (years)
1.0-9.9 10.0-17.9 18.0-45.0
No. of patients (%) 168 96 (57) 38 (23) 34 (20)
Treatment phase
SR/IR consolidation 1 63 (38) 44 (46) 13 (34) 6 (18)
SR/IR delayed intensiﬁcation 1/consolidation 2 46 (27) 19 (20) 11 (29) 16 (46)
SR/IR maintenance 1 30 (18) 18 (19) 6 (16) 6 (18)
HR block treatment 27 (16) 15 (15) 6 (16) 6 (18)
HR delayed intensiﬁcation 1 (0.5) 0 1 (2.5) 0
HR maintenance 1 1 (0.5) 0 1 (2.5) 0
Symptoms at AAP diagnosis
Abdominal pain* 166 (99) 94 (98) 38 (100) 34 (100)
Vomiting/missing 106 (66)/7 60 (64)/2 28 (80)/3 18 (56)/2
Nausea/missing 113 (74)/16 59 (68)/9 30 (91)/5 24 (75)/2
Back pain/missing 36 (26)/27 17 (22)/18 11 (34)/6 8 (26)/3
AAP grade†
1 21 (13) 19 (20) 0 2 (6)
2 140 (83) 72 (75) 37 (97) 31 (91)
3 3 (2) 1 (1) 1 (3) 1 (3)
Missing 4 4 0 0
ASP re-exposure‡ 34 (20) 28 (29) 3 (8) 3 (9)
Second AAP 15 (44) 11 (39) 2 (67) 2 (67)
NOTE. All data are No. (%).
Abbreviations: AAP, asparaginase-associated pancreatitis; ASP, asparaginase; HR, high risk; IR, intermediate risk; SR, standard risk.
*Abdominal pain persisted . 72 hours in 80% of the patients with AAP with this information available (124/155, unknown in 13 patients).
†Grading included: (1) mild AAP with symptoms and enzyme elevations lasting , 72 hours; (2) severe AAP with symptoms and/or enzyme
elevations lasting . 72 hours or hemorrhagic pancreatitis, pancreatic abscess, or pseudocyst; and (3) death from AAP.
‡Two patients with planned polyethylene glycol conjugated Escherichia coli–derived ASP (PegASP) re-exposure developed a second episode
of acute pancreatitis before restart of PegASP (not included). PegASP was replaced with Erwinia chrysanthemi-derived ASP due to allergy in
3 patients after the ﬁrst AAP event, of whom none developed a second AAP. Five patients developed ﬁrst-time AAP after the last ASP dose in
the protocol treatment and, thus, could not be rechallenged with PegASP.
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$ 3 times the upper normal limit; and (3) ultrasound, com-
puted tomography, or magnetic resonance imaging com-
patible with pancreatitis according to the international Ponte
di Legno consensus criteria.29 The deﬁnition of AAP in this
study required a diagnosis within 4 weeks after the last ASP
injection—the cutoff time point of measurable polyethylene
glycol conjugated Escherichia coli–derived ASP (PegASP)
acitivity.30 Deﬁnitions of grading and complications are
presented in the Data Supplement and Tables 1 and 2.
ALL2008 Protocol Treatment
Therapy details on the NOPHO ALL2008 protocol have
been reported previously.2,27,28,31 Treatment was based
on stratiﬁcation into 4 risk groups: standard risk (SR);
intermediate risk (IR); high risk (HR); and high risk with
hematopoietic stem cell transplantation (HR-SCT) in ﬁrst
complete remission (CR1), guided by tumor burden at
diagnosis, immunophenotype, cytogenetics, CNS in-
volvement, and minimal residual disease levels on treat-
ment days 15, 29, and 79 (or after the second HR block).
SR and IR patients received identical PegASP treatment. Of
note, children (SR and IR) were randomly assigned to
receive PegASP, 1,000 IU/m2/dose intramuscularly, either
at 2-week (control arm) or 6-week (experimental arm)
intervals from weeks 14 to 33 (ClinicalTrials.gov identiﬁer:
NCT00819351). All children received PegASP at 6-week
intervals from week 14 after the randomization closed on
March 1, 2016.32 The randomization did not inﬂuence
TABLE 2. AAP-Related Complications
Complication All 1.0-9.9 years 10.0-17.9 years 18.0-45.0 years
SIRS* 103 (72)/24 66 (75)/8 22 (88)/6 15 (63)/10
Body temperature . 38°C or , 36°C/missing 57 (35)/6 35 (37)/2 14 (40)/3 8 (24)/1
Heart rate . 90 beats/min/missing 107 (69)/14 64 (69)/3 24 (71)/4 19 (70)/7
Respiratory rate . 20 breaths/min/missing 43 (37)/53 31 (42)/23 9 (38)/14 3 (17)/16
WBC . 12 3 109/L or , 4 3 109/L/missing 98 (61)/7 62 (68)/5 19 (51)/1 17 (52)/1
Systolic blood pressure # 100 mmHg 52 (33)/11 28 (30)/3 17 (49)/3 7 (24)/5
ICU admission 65 (39) 30 (31) 21 (55) 14 (41)
Assisted mechanical ventilation 14 (22) 7 (23) 4 (19) 3 (21)
Vasopressor support/missing 18 (29)/2 6 (20) 7 (37)/2 5 (36)
Need of acute insulin therapy† 32 (19) 11 (11) 14 (37) 7 (21)
Need of permanent insulin therapy 18 (11) 3 (3) 8 (21) 7 (21)
Pancreatic pseudocysts 45 (27)/1 15 (16)/1 17 (45) 13 (38)
Drainage 19 (42) 4 (27) 11 (65) 4 (31)
Recurrent abdominal pain at last follow-up 15 (10)/11 6 (7)/6 7 (23)/4 2 (6)/1
Elevated pancreatic enzymes at last follow-up 9 (6)/19 3 (3)/10 5 (17)/8 1 (3)/1
Imaging compatible with pancreatitis at last follow-up 11 (7)/15 3 (3)/10 6 (18)/4 2 (6)/1
Inﬂammation/edema‡ 3 (27) 2 (67) 0 1 (50)
Pancreatic pseudocysts§ 6 (55) 1 (33) 3 (50) 2 (100)
Hemorrhage|| 2 (18) 0 2 (33) 0
AAP-related death¶ 3 (2) 1 (1) 1 (3) 1 (3)
Any complication# 95 (57) 44 (46) 31 (82) 20 (59)
Any acute complication 90 (54) 40 (42) 30 (79) 20 (59)
Any persisting complication 33 (20) 8 (8) 16 (42) 9 (26)
NOTE. All data are No. (%) or No. (%)/missing.
Abbreviations: AAP, asparaginase-associated pancreatitis; ICU, intensive care unit; SIRS, systemic inﬂammatory response syndrome.
*SIRS deﬁnition:$ 2 of 4 criteria, including body temperature. 38 or, 36°C, heart rate. 90 beats/min, respiratory rate. 20 breaths/min,
and WBC . 12 3 109/L or , 4 3 109/L.
†One patient presented with diabetic ketoacidosis at AAP diagnosis.
‡Persisting inﬂammation/edema in 1 patient and development of inﬂammation/edema after AAP diagnosis in 1 patient.
§Persisting pseudocysts in 3 patients and development of pseudocysts after AAP diagnosis in 3 patients.
||Development of hemorrhage after AAP diagnosis in 2 patients.
¶AAP diagnosis postmortem in 1 patient.
#Any known complication included acute complications (ICU admission, acute insulin need, development of pancreatic pseudocysts, and
AAP-related death) and persisting complications (permanent insulin need, recurrent abdominal pain, elevated pancreatic enzymes at last
follow-up, and imaging compatible with pancreatitis at last follow-up).
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cure rates.32 Patients aged $ 18 years and treated at an
adult clinic were not included in the PegASP randomi-
zation; however, adults from Estonia, Lithuania, and
Sweden received PegASP at 6-week intervals from
March, September, and April 2016, respectively. The
adult centers from the remaining countries continued
PegASP treatment according to the control arm. The
NOPHO ALL2008 protocol is presented in the Data
Supplement.
The study was approved by the regional research ethics
committee of the Capital Region of Denmark (Protocol No.
H-2-2010-002) and the Danish Data Protection Agency
(Journal No. 2012-58-0004). All patients gave written in-
formed consent, and the study was conducted in accor-
dance with the Declaration of Helsinki (version 2008;
www.wma.net).
Statistical Analyses
Patients were followed from the time of ALL diagnosis until
the date of the ﬁrst event (relapse, death during induction
or in CR1, or second malignant neoplasm [SMN]); SCT in
CR1; loss to follow-up/abandonment of therapy; or last
follow-up in the registry or April 2, 2019, whichever came
ﬁrst. When exploring AAP, patients were followed from day
30 (the time of the ﬁrst ASP dose) until the date of the ﬁrst
event including censoring 4 weeks after the last planned
ASP injection or 4 weeks after the ASP truncation date,
if available, respectively. The reversed Kaplan-Meier
method was used to estimate the follow-up time. Cu-
mulative incidences were estimated using the Aalen-
Johansen estimator considering relapse, death, and
SMN as competing events; the estimates were compared
using Gray’s test. The body mass index z-scores were
calculated accounting for age and sex according to
Danish references.33 Time to ﬁrst AAP was analyzed in
a Cox proportional hazards regression model including
relevant preselected clinical characteristics. As a sensi-
tivity analysis of the predeﬁned age groups (1.0-9.9 years,
10.0-17.9 years, and 18.0-45.9 years), new age groups
were explored, each containing approximately 25% of the
AAP events (1.0-4.9 years, 5.0-8.9 years, 9.0-16.9 years,
and 17.0-45.9 years). Investigating potential risk factors of
AAP-related complications, preselected clinical variables
were included in a multiple logistic regression model of
development of any AAP-related complication within
$ 100 days after the AAP diagnosis. To investigate the
association between AAP and time to death in CR1 and
relapse, we used Cox models with AAP as a time-
dependent variable and delayed entry on the CR1 date,
respectively. As sensitivity analyses, the models were
stratiﬁed by risk group on day 29 with delayed entry on day
29 or the CR1 date, if later than day 29. In all Cox models,
relevant interactions and the proportional hazards as-
sumption were explored. Two-sided P values , .05 were
regarded as statistically signiﬁcant.
RESULTS
Patient and Treatment Characteristics
Following all patients for a median of 245 days (inter-
quartile range [IQR], 186-259), the day 280 cumulative
incidence of ﬁrst-time AAP (168/2,448) was 8.3% (95%
CI, 7.0 to 9.9) with all but 1 late AAP included at this time
point. The day 280 cumulative incidences were 7.0%
(95% CI, 5.4 to 8.6), 10.1% (95% CI, 7.0 to 13.3), and
11.0% (95% CI, 7.1 to 14.9) in patients aged 1.0-9.9
years, 10.0-17.9 years, and 18.0-45.9 years, respectively
(P = .03; Data Supplement). However, when analyzing the
4 new age groups, the risk of AAP already rose at 5 years of
age, being 5.4% (95% CI, 3.2 to 7.5) in patients aged 1.0-
4.9 years, 10.2% (95% CI, 7.2 to 13.1) in patients aged
5.0-8.9 years, 10.4% (95% CI, 7.3 to 13.4) in patients
aged 9.0-16.9 years, and 11.3% (95% CI, 7.6 to 14.9) in
patients aged 17.0-45.9 years (P , .001; Fig 1). The
clinical characteristics of the patients appear in Tables 1
and 3. None of the patients had a prior history of pan-
creatitis or any known comorbidity, particularly of the liver
and pancreas.
AAP occurred within a median of 10 days (IQR, 6-13;
range, 0-28) from last PegASP exposure after a median
number of 5 PegASP doses in total (IQR, 3-7; range, 1-
14). PegASP was replaced with Erwinia chrysanthemi-
derived ASP because of allergy in 1 patient before the
AAP event. The PegASP activity was measurable in 98%
of the AAP patients during treatment with this information
available (86/88, unknown in 80 patients). Of note, in 6 of
the excluded 8 patients with acute pancreatitis occurring
more than 4 weeks after the last PegASP dose, acute
pancreatitis occurred within 32-90 days (median,
38 days) after the last PegASP dose. The remaining
2 patients developed acute pancreatitis 210 and 589
days, respectively, after the last PegASP dose (Data
Supplement).
In a multiple Cox regression analysis (including sex,
immunophenotype, and WBC), the hazard of AAP was
doubled already since the age of 5 years (Table 4).
Hence, patients aged 5.0-8.9 years demonstrated an
HRa of 2.3 (95% CI, 1.5-3.6; P , .0001), patients aged
9.0-16.9 years demonstrated an HRa of 2.5 (95% CI,
1.6-3.8, P , .0001), and patients aged 17.0-45.9 years
demonstrated an HRa of 2.5 (95% CI, 1.6 to 3.8;
P , .0001; Table 4). No difference in the estimates was
observed when including the initially excluded 8 pa-
tients diagnosed with acute pancreatitis more than
4 weeks after the last PegASP dose as a sensitivity
analysis (results not shown). Additionally, the above-
mentioned associations remained unchanged when
stratifying by induction glucocorticoids (prednisolone
v dexamethasone) or by day 29 minimal residual
disease-guided risk group (SR v IR v HR/HR-SCT), re-
spectively (results not shown).
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AAP-Related Complications and Mortality
Of the 9 patients who presented with hemorrhagic and/or
necrotizing pancreatitis at AAP diagnosis, 33% (3/9) had
persisting symptoms and signs of chronic pancreatitis at
last follow-up, and 1 of these died as a result of AAP
(Table 2). Forty-ﬁve patients developed pseudocysts (27%;
45/167 with this information available), of whom 21%
(9/43; unknown in 2 patients) had recurrent abdominal
pain at last follow-up (Table 2).
In a sex-adjusted multiple logistic regression of any AAP-
related complication (ie, AAP-related death; intensive
care unit admission; acute and permanent need for in-
sulin therapy; development of pancreatic pseudocysts;
recurrent abdominal pain; elevated pancreatic enzymes at
last follow-up; and imaging at last follow-up showing
pancreatic inﬂammation/edema, pseudocysts, or hem-
orrhage), only patients with $ 100 days of follow-up after
the AAP diagnosis (160/168) were included (median
follow-up, 2.3 years; IQR, 1.3-4.2). Patients aged 10.0-
17.9 years demonstrated more than 4-fold increased odds
of developing any of these AAP-related complications
(OR, 4.4; 95% CI, 1.7 to 11.2; P = .002), compared with
patients aged 1.0-9.9 years (Table 5). Neither age
$ 18.0 years (OR, 1.5; 95% CI, 0.7 to 3.5; P = .3)
compared with children aged 1.0-9.9 years nor sex was
associated with development of any AAP-related com-
plication (Table 5). When including the 4 new age groups
as a sensitivity analysis, both adolescents aged 9.0-
16.9 years and adults aged 17.0-45.9 years had
increased odds of developing any AAP-related compli-
cation (9.0-16.9 years: OR, 7.3, 95% CI, 2.7 to 19.7;
P = .0001; and 17.0-45.9 years: OR, 2.6; 95% CI, 1.1 to
6.4; P = .04; Data Supplement), compared with children
aged 1.0-4.9 years.
When analyzing development of any acute AAP-related
complication (ie, AAP-related death, acute insulin need,
intensive care unit admission, and pancreatic pseudocyst
development), only patients aged 10.0-17.9 years had
increased odds of developing any acute complication
(OR, 5.2; 95% CI, 2.1 to 13.2; P = .0005), compared
with patients aged 1.0-9.9 years (Table 5; Data Sup-
plement). Odds of developing any persisting AAP-related
complication (ie, elevated pancreatic enzymes at last
follow-up; imaging at last follow-up showing pancre-
atic inﬂammation/edema, pseudocysts, or hemorrhage;
permanent insulin need; and recurrent abdominal
pain) were increased for patients aged 10.0-17.9 years
(OR, 6.7; 95% CI, 2.4 to 18.4; P = .0002) and patients
aged 18.0-45.9 years (OR, 4.1; 95% CI, 1.4 to 11.8;
P = .01), compared with patients aged 1.0-9.9 years
(Table 5; Data Supplement). Notably, in the sensitivity
analysis, patients aged 5.0-8.9 years did not have in-
creased odds of developing any persisting AAP-related
complication (OR, 1.7; 95% CI, 0.3 to 10.8; P = .6),
compared with patients aged 1.0-4.9 years (Data
Supplement).
Death from any cause occurred as the ﬁrst event in 81 of
2,448 patients, including 5 AAP patients, of whom 3 aged
8.6, 17.3, and 18.6 years died as a result of ﬁrst-time AAP
within 0-29 days from AAP diagnosis (AAP was an un-
expected autopsy ﬁnding in 1 patient). In an age- and
sex-adjusted Cox analysis of time to death in CR1, no
difference was found when comparing AAP patients with
non-AAP patients (HRa, 0.4; 95% CI, 0.05 to 2.6; P = .3;
remaining results not shown). Stratifying the above-
mentioned models by risk group on day 29 did not change
the results.
Asparaginase Re-Exposure and Relapse
Approximately one ﬁfth (34/168) of the patients with AAP
were rechallenged with ASP, of whom 44% (15/34) de-
veloped a second episode of AAP after a median of 2 ASP
doses (IQR, 1-3; range, 1-7); 40% (6/15) were severe
(Table 1). Development of a second AAP episode after ASP
re-exposure was not signiﬁcantly associated with age (Data
Supplement). No patient with a second AAP episode was
further re-exposed to ASP.
Leukemic relapse in CR1 occurred in 196 of 2,448
patients during the study period, including 21 AAP
patients, among whom PegASP was truncated in 81%
(17/21) because of AAP. The age- and sex-adjusted
hazard of relapse among patients with AAP who were
truncated in ASP was not signiﬁcantly increased when
comparing with patients with AAP who were re-exposed
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FIG 1. The cumulative incidence of ﬁrst-time asparaginase-associated
pancreatitis (AAP) by age groups with 95%CIs and patients at risk. The
day 280 cumulative incidences were 5.4% (95% CI, 3.2 to 7.5) for
patients aged 1.0-4.9 years; 10.2% (95% CI, 7.2 to 13.1) for patients
aged 5.0-8.9 years; 10.4% (95% CI, 7.3 to 13.4) for patients aged 9.0-
16.9 years; and 11.3% (95% CI, 7.6 to 14.9) for patients aged 17.0-
45.9 years. Of note, day 280 from acute lymphoblastic leukemia
diagnosis to event corresponds to day 250 on the x-axis because of
entry for all patients on day 30 (the time of the ﬁrst polyethylene glycol
conjugated Escherichia coli–derived ASP [PegASP] dose).
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to ASP (5.0-year cumulative incidence of relapse:
13.2% v 14.2%; HRa, 1.0; 95% CI, 0.3 to 3.1; P = .97).
Moreover, no difference between patients with AAP
versus patients without AAP was found in an age- and
sex-adjusted Cox analysis (HRa, 1.7; 95% CI, 0.8 to 3.3;
P = .1; remaining results not shown). Stratifying the
abovementioned models by risk group on day 29 did not
change the results.
DISCUSSION
Despite superior cure rates for children versus adults with
ALL, many centers do not use pediatric ALL protocols,
partly because of worries about risk of toxicities. Because
ASP plays a crucial role in pediatric ALL protocols, the
present ﬁndings of no increased AAP risk in adults compared
with children down to the age of 5 years—in spite of an ASP-
heavy protocol—are comforting and in accordance with
TABLE 3. Baseline Characteristics
Characteristic No. (%)
Day 280 Cumulative Incidence of
First-Time AAP (%) 95% CI P
All patients (delayed entry on day 30) 2,380 8.3 7.0 to 9.9 —
Age groups (years; predeﬁned) .03
1.0-9.9 1,587 (67) 7.0 5.4 to 8.6
10.0-17.9 415 (17) 10.1 7.0 to 13.3
18.0-45.9 378 (16) 11.0 7.1 to 14.9
Age groups (years; sensitivity analysis) , .001
1.0-4.9 1,065 (45) 5.4 3.2 to 7.5
5.0-8.9 453 (19) 10.2 7.2 to 13.1
9.0-16.9 435 (18) 10.4 7.3 to 13.4
17.0-45.9 427 (18) 11.3 7.6 to 14.9
Sex .8
Female 1,019 (43) 7.7 5.9 to 9.4
Male 1,361 (57) 8.7 6.6 to 10.8
Immunophenotype .4
BCP 1,992 (84) 8.8 6.9 to 10.8
T -cell 388 (16) 6.9 4.2 to 9.6
WBC .2
, 100 3 x109/L 2,056 (86) 8.8 7.0 to 10.7
$ 100 3 x109/L 323 (14) 6.3 3.5 to 9.2
Missing 1 — —
BMI .5
# 22 SD 117 (5) 7.1 2.4 to 11.8
. 22 SD to , +2 SD 2,066 (87) 8.2 6.6 to 9.8
$ +2 SD 164 (7) 9.8 5.1 to 14.6
Missing 33 (1) — —
Induction treatment .1
Dexamethasone 539 (23) 6.2 4.1 to 8.4
Prednisolone 1,841 (77) 9.5 7.0 to 12.1
Treatment group day 29* .6
SR 1,057 (44) 8.8 5.8 to 11.9
IR 875 (37) 10.8 5.3 to 16.4
HR/HR-SCT 429 (18) 7.1 4.5 to 9.8
Missing 19 (1) — —
Abbreviations: AAP, asparaginase-associated pancreatitis; BCP, B-cell precursor; BMI, body mass index; HR/HR-SCT, high risk/high risk with
hematopoietic stem cell transplantation; IR, intermediate risk; SD, standard deviations; SR, standard risk.
*Protocol treatment was modiﬁed with the addition of 1 cycle of blinatumomab because of poor treatment response in 1 patient, nelarabine
because of poor treatment response in 2 patients, and imatinib because of BCR-ABL translocation in 1 patient.
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previous studies.34,35 Moreover, our ﬁndings are compatible
with previous pediatric studies reporting more than a 2-fold
increasedAAP risk in patients older than 9 years of age.3,4,8,15,25
This similarity between older children and young adults with
ALL has also recently been demonstrated for thromboembolic
complications.2
Additionally, the odds of any AAP-related complication
were increased by more than 7-fold in adolescents aged
9.0-16.9 years and more than 2-fold in adults aged 17.0-
45.9 years, compared with younger children aged 1.0-4.9
years. In fact, adolescents had the most pronounced
increase in odds, demonstrating more than 7-fold in-
creased odds of any acute complication and more than
12-fold increased odds of any persisting complication,
compared with the youngest children. This emphasizes
the striking vulnerability of this age group, although the
reasons hereof are unknown. Changes in endogenous sex
hormones may give rise to the increased frequency of
insulin resistance and (pre)metabolic syndrome during
puberty,36 which has been associated with dyslipidemia
and decreased antioxidant capacity.37 Oxidative stress
and inﬂammation play a pivotal role in the pathogenesis of
pancreatitis—and probably also in the development of
pancreatitis-related complications.38,39
In contrast to age, the role of genetic predisposition is less
clear. Recent genome-wide association studies have found
different candidate single-nucleotidepolymorphisms asso-
ciated with pancreatitis in patients with ALL5,9,26; how-
ever, only rs13228878 and rs10273639 associated with
TABLE 4. Multiple Cox Regression Analysis of Time to First AAP (n = 2,379)
Variable No. AAP-Speciﬁc HRa 95% CI P
Cox model 1
Age groups (years; predeﬁned)
1.0-9.9 1,587 ref
10.0-17.9 415 1.6 1.1 to 2.3 .02
18.0-45.9 377 1.6 1.1 to 2.4 .02
Sex
Female 1,018 ref
Male 1,361 1.0 0.8 to 1.4 .9
Immunophenotype
BCP 1,992 ref
T cell 387 0.8 0.5 to 1.3 .3
WBC
, 100 3 109/L 2,056 ref
$ 100 3 109/L 323 0.8 0.5 to 1.3 .4
Cox model 2
Age groups (years; sensitivity analysis)
1.0-4.9 1,065 ref
5.0-8.9 453 2.3 1.5 to 3.6 , .001
9.0-16.9 435 2.5 1.6 to 3.8 , .001
17.0-45.9 426 2.5 1.6 to 3.8 , .001
Sex
Female 1,018
Male 1,361 1.0 0.8 to 1.4 .8
Immunophenotype
BCP 1,992 ref
T cell 387 0.7 0.4 to 1.1 .1
WBC
, 100 3 109/L 2,056 ref
$ 100 3 109/L 323 0.8 0.5 to 1.3 .4
NOTE. The table includes 2 Cox models including the predeﬁned age groups and the new age groups as sensitivity analysis, respectively.
Abbreviations: AAP, asparaginase-associated pancreatitis; BCP, B-cell precursor; HRa, AAP hazard ratios; ref, reference.
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elevated expression of the PRSS1 gene encoding for
trypsinogen have been validated.26
The early onset of AAP coincided with the PegASP
administration, yet the cumulative PegASP dose up to
the time of AAP ranged from 1,000 to 14,000 IU/m2.
Substantial evidence supports that the AAP risk is
proportional to the number of doses administered.9,32
Notably, this is in contrast to ASP hypersensitivity, which
in general occurs after the ﬁrst few doses.40 Although
premature withdrawal of ASP has been linked to inferior
survival4 and PegASP was truncated in the majority of
patients with AAP (80%) in our study, neither AAP nor
truncation of ASP because of AAP was associated with
increased risk of relapse, potentially reﬂecting low study
power in this regard. When looking at ASP re-exposure,
44% of those who were rechallenged with PegASP in our
study developed a second event of acute pancreatitis
(40% being severe cases), which is in accordance with
previous ﬁndings in pediatric studies.5,18 Thus, current
guidelines for children with ALL recommend ASP re-
exposure only in patients who within 48 hours have no
symptoms, normalized pancreatic enzymes, and no evi-
dence of pseudocysts or necrosis.23 Of note, these
guidelines are based on classiﬁcation of acute pancrea-
titis according to the original Atlanta criteria—dis-
tinguishing between severe (lasting . 48 hours) and
nonsevere (lasting # 48 hours) acute pancreatitis.41,42
For adolescents and adults with ALL, some expert panel
guidelines recommend permanent discontinuation of
ASP for clinically acute pancreatitis (vomiting and se-
vere abdominal pain with elevated pancreatic enzymes
above 3 times the upper normal limit and/or pseudocyst
development).43 However, the pressing question in re-
lation to (1) the AAP risk in AAP-naive patients, (2) the
risk of a second AAP episode after ASP re-exposure, and
(3) overall survival after AAP-related ASP truncation
remains unanswered: Who needs more, less, or no ASP?
In that respect, the lack of association between char-
acteristics of the ﬁrst and second AAP is important,
which supports that the decision on re-exposure pri-
marily should reﬂect the anticipated risk of leukemic
relapse—except for patients having persisting symp-
toms from their ﬁrst AAP.
The main strengths of this study include the international,
multicenter, and population-based design and the in-
clusion of uniformly treated patients with the same di-
agnosis across a wide age span. Additionally, the online
mandatory prospective and systematic registration of 20
predeﬁned treatment-related toxicities strengthens the
reliability of the ﬁndings.27
The limitations include the lack of power regarding the
analyses of leukemic relapse and second AAP event.
Moreover, a potential introduction of selection bias in
favor of patients with clear-cut symptoms exists because
no systematic screening of AAP was performed in pa-
tients with abdominal pain or systemic inﬂammatory
response syndrome. Thus, AAP can easily be mis-
interpreted as sepsis, unless pancreatic enzyme levels
are measured.18 Still, the impact of age on AAP incidence
and risk of complications stands strong, and it is unlikely
that these potential weaknesses would have markedly
inﬂuenced the ﬁndings.
In conclusion, older children and adults had similar AAP
risk, whereas morbidity was most pronounced among
adolescents. ASP re-exposure should be considered only
for patients with an anticipated high risk of leukemic re-
lapse, because multiple studies strongly indicate that re-
duction of ASP treatment intensity increases the risk of
relapse.4,44,45
TABLE 5. Multiple Logistic Regression of AAP-Related Complications (n = 160)
AAP-Related Complication No. OR* 95% CI P
Any AAP-related complication*
Age groups (years; predeﬁned)
1.0-9.9 93 ref
10.0-17.9 34 4.4 1.7 to 11.2 .002
18.0-45.9 33 1.5 0.7 to 3.5 .3
Sex
Female 71 ref
Male 89 1.2 0.6 to 2.3 .6
Any acute AAP-related complication†
Age groups (years; predeﬁned)
1.0-9.9 93 ref
10.0-17.9 34 5.2 2.1 to 13.2 , .001
18.0-45.9 33 1.8 0.8 to 4.1 .1
Sex
Female 71 ref
Male 89 1.3 0.7 to 2.6 .4
Any persisting AAP-related complication‡
Age groups (years; predeﬁned)
1.0-9.9 93 ref
10.0-17.9 34 6.7 2.4 to 18.4 , .001
18.0-45.9 33 4.1 1.4 to 11.8 .01
Sex
Female 71 ref
Male 89 0.9 0.4 to 2.0 .7
Abbreviations: AAP, asparaginase-associated pancreatitis; OR, odds ratio; ref,
reference; ref, reference.
*OR of any AAP-related complication (acute and persisting).
†OR of any AAP-related complication including intensive care unit admission,
acute insulin therapy, development of pancreatic pseudocysts, and AAP-
related death.
‡OR of any persisting AAP-related complication including permanent insulin
therapy, recurrent abdominal pain at last follow-up, elevated pancreatic enzymes at
last follow-up, and imaging compatible with pancreatitis at last follow-up.
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